|
Bringing confidence to decision making in breast cancerRecent studies in genomic testing are giving us confidence for deciding if breast cancer patients will benefit from having chemotherapy.
 Prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancerBy Oleg Gluz, MDWatch
PlanB is the first study that provides prospective data with the 21-gene Recurrence Score® (Oncotype DX®) assay in patients with high clinical risk of recurrence, including node-positive disease. Dr Oleg Gluz, one of the two scientific coordinators of PlanB, explains how the study findings to date compare with previous studies as well as how they may be interpreted for risk stratification of patients.
|